NCLT sanctions amalgamation of Max Healthcare subsidiaries Crosslay Remedies and Jaypee Healthcare
NCLT approved the amalgamation of Max Healthcare's wholly-owned subsidiaries, Crosslay Remedies and Jaypee Healthcare, effective October 5, 2024, streamlining operations and addressing regulatory concerns.
The amalgamation streamlines the corporate structure of Max Healthcare by merging two subsidiaries. While it is an internal reorganization, the NCLT approval is a crucial step that resolves potential legal and financial complexities, leading to improved operational efficiency and a stronger consolidated entity.
The NCLT's sanctioning of the amalgamation provides regulatory clarity and allows for the operational consolidation of two wholly-owned subsidiaries, which is a positive step for the parent company. It also addresses and resolves previous concerns raised by regulatory bodies.
* Max Healthcare Institute Limited (MAXHEALTH) announced that the Hon’ble National Company Law Tribunal (NCLT), Chandigarh Bench, issued an Order on November 7, 2025, sanctioning the Scheme of Amalgamation between its wholly-owned subsidiaries, Crosslay Remedies Limited (CRL) and Jaypee Healthcare Limited (JHL). * The Appointed Date for the Scheme is October 5, 2024. * Under the sanctioned Scheme: * CRL, the Transferor Company, will be dissolved without winding up. * All properties, rights, powers, liabilities, and duties of CRL will be transferred to and vested in JHL, the Transferee Company, with effect from the Appointed Date. * Existing legal, taxation, and other proceedings against CRL will continue against JHL. * All contracts of CRL will transfer to JHL. * Employees of CRL will become employees of JHL on terms no less favorable than their current engagement, effective from the Appointed Date. * The authorized share capital of JHL will increase by vesting CRL's authorized share capital, resulting in a combined authorized share capital of ₹7,57,00,00,000. * No new equity shares will be issued as both companies are wholly-owned subsidiaries, and existing shares of CRL held by the Holding Company will be extinguished. * The NCLT considered and addressed observations from the Regional Director/Registrar of Companies (RD/RoC) and the Income Tax Department (ITD) regarding contingent liabilities (including civil cases and consumer claims amounting to ₹2,523 lakh, a Ghaziabad Development Authority demand of ₹139 lakh, PF compliance, and income tax disputes), financial losses of JHL in previous fiscal years (₹614.71 lakh in FY 2024-25 and ₹6,270.73 lakh in FY 2023-24), and the proposed accounting treatment. * The Petitioner Companies provided clarifications stating that the Scheme adequately addresses all liabilities, ensures accounting compliance with applicable standards, and that JHL's going concern status is validated by the positive cash flow business of CRL and the strong net worth of the ultimate Holding Company, Max Healthcare Institute Ltd. * The NCLT concluded that the observations did not impede the sanctioning of the scheme, finding it bona fide and in the interest of shareholders and creditors.
What to do with a filing like this
Max Healthcare Institute Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Max Healthcare Institute Limited. Read the original for the full detail.